YD Bio, EG BioMed Launch AI Cancer Risk Assessment
MT newswire2026/10/06 13:0709:07 AM EDT, 10/06/2026 (MT Newswires) -- YD Bio (YDES) said Tuesday it launched along with EG BioMed an AI-powered cancer risk assessment that organizes self-reported health information into personalized reports covering 10 cancer types. The 52-question assessment takes about 10 minutes and provides low, moderate or high risk stratification based on a 48-feature pan-cancer model and 10 cancer-specific models, YD Bio said. The service is available in English and Chinese for a promotional price of $10, reduced from $50, the company said. YD Bio said the tool does not diagnose cancer or replace medical evaluation. Shares of YD Bio were down 7.7% in premarket activity Tuesday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
